January 2026 has marked a vibrant start for the biomedical venture capital market with the launch of three new funds, focused on accelerating therapeutic breakthroughs and medical technology across the Atlantic.
Key investment funds and strategic focus
-
Andreessen Horowitz (A16z): The Silicon Valley giant allocated $700 million to its “Bio and Health” division as part of a larger $15 billion fundraising effort. The fund aims to integrate artificial intelligence (AI) and data technology to maintain the technological edge of the U.S. healthcare sector.
-
PxB Seed Fund (Penn-BioNTech): A collaboration between the University of Pennsylvania, BioNTech, and Osage University Partners has established a $50 million fund. This initiative prioritizes early-stage startups spinning out of Penn’s scientific research, particularly in cell therapy and diagnostics.
-
Servier Ventures: The French pharmaceutical group Servier launched a €200 million (approximately $232 million) venture fund. Unlike the other two, Servier Ventures primarily targets European biotechs, with a strategic focus on oncology and neurology.
A shared vision These investments highlight a clear trend: the shift from basic research to rapid commercialization supported by large corporate entities. The emphasis on AI, personalized therapies, and bolstering domestic health infrastructure is seen as vital for ensuring health security and global competitiveness in the new era.
Source: https://www.fiercebiotech.com/biotech/3-new-venture-funds-collect-nearly-1b-biotech-us-eu